Navigation Links
Lexicon To Present At The BIO CEO & Investor Conference
Date:2/6/2013

THE WOODLANDS, Texas, Feb. 6, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands , M.D., Ph.D., President and Chief Executive Officer, will present at the Bio CEO & Investor Conference on Monday, February 11, at 11:00 AM EST in New York City. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones.

A webcast of the presentation will be available through Lexicon´s website at www.lexpharma.com. An archived version of the presentation will be available at www.lexpharma.com until March 11, 2013.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Provide First Quarter 2012 Financial Results
2. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
3. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
4. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
5. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
6. Lexicon Announces Positive Results of LX4211 Phase 2b Trial For Type 2 Diabetes
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Lexicon to Provide Second Quarter 2012 Financial Results
9. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
10. Lexicon Pharmaceuticals To Present At The Wedbush PacGrow 2012 Management Access Conference
11. Lexicon Pharmaceuticals Reports Preliminary Results From Two Phase 1 Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2017)... Aug. 31, 2017 PM360,s annual Innovations ... to the latest innovations happening across the industry. Established ... to focus on providing a comprehensive look at the ... covers the most innovative companies, startups, divisions, products, services, ... "Everyone in this industry wants to ...
(Date:8/29/2017)... 2017 In a move that promises to ... for veterinary practices of all sizes, Cubex LLC and ... makes TITAN,s expertise in physical security, drug diversion investigations, ... nationally. "Every ... substances is at risk today," said TITAN founder and ...
(Date:8/28/2017)... , Aug. 28, 2017   Aesculight ®, a division of ... surgical lasers. Built on over 20 years of American veterinary laser ... New and Exclusive VetScalpel®Features and Enhancements ... Duclos, DVM, is excising a tumor with his new VetScalpel laser. Dr. ... Lynnwood, WA. ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... “Monique”: is the ... situations. “Monique” is the creation of published author, Colleen Crispi, has owned four beauty ... Crispi has been involved in real estate and cooking. , “The doctor’s office ...
(Date:9/19/2017)... ... ... Only a few physicians were selected to receive the prestigious 2016 Patients' Choice ... . The founder and medical director of Clevens Face and Body Specialists , ... and the University of Michigan. He has served patients throughout Central Florida and beyond ...
(Date:9/19/2017)... ... 2017 , ... PAPA Healthcare, Inc. announced today, the release ... helps fill gaps, provide essential insights, and improve productivity.” The story focuses ... PAPA Healthcare’s post-acute productivity and analytics solutions. , St. Vincent’s Home Infusion provides ...
(Date:9/19/2017)... ... 19, 2017 , ... Peter Chandonait, Abt Associates Principal Scientist ... (PMI) Africa Indoor Residual Spraying (AIRS) Project , has been named the Grand ... Action Award, a USAID Catalyst Award, recognizes USAID staff and implementing partners who ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... return to Texas as a part of its national Swirl: A Wine Tasting ...
Breaking Medicine News(10 mins):